1.22
3.94%
-0.05
After Hours:
1.25
0.03
+2.46%
AdvisorShares Psychedelics ETF stock is currently priced at $1.22, with a 24-hour trading volume of 26,664.
It has seen a -3.94% decreased in the last 24 hours and a -6.87% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.26 pivot point. If it approaches the $1.19 support level, significant changes may occur.
Previous Close:
$1.27
Open:
$1.27
24h Volume:
26,664
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.17%
1M Performance:
-6.87%
6M Performance:
-7.58%
1Y Performance:
-29.48%
AdvisorShares Psychedelics ETF Stock (PSIL) Company Profile
Name
AdvisorShares Psychedelics ETF
Sector
Industry
Phone
(202) 684-6383
Address
-
AdvisorShares Psychedelics ETF Stock (PSIL) Latest News
Investors Warm Up to Psychedelics as FDA Reviews Treatment for PTSD - BNN Bloomberg
BNN Bloomberg
LSD, Ecstasy Lure Traders Betting on 'Psychedelic Renaissance' - Bloomberg
Bloomberg
Mental Health Mavericks: 3 Stocks Changing the Game - Yahoo Finance
Yahoo Finance
Psychedelic Funding & Public Markets in 2023 - Psychedelic Alpha
Psychedelic Alpha
Will Psychedelics Companies Win The Mental Health Boom? - Finimize
Finimize
How to Invest in Psychedelics - Investing News Network
Investing News Network
AdvisorShares Psychedelics ETF Stock (PSIL) Financials Data
There is no financial data for AdvisorShares Psychedelics ETF (PSIL). Check out other stocks for more information.
About AdvisorShares Psychedelics ETF
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
Cap:
|
Volume (24h):